KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Novartis Ag (NVS) Interest Expenses (2016 - 2025)

Historic Interest Expenses for Novartis Ag (NVS) over the last 17 years, with Q4 2025 value amounting to -$304.0 million.

  • Novartis Ag's Interest Expenses fell 1054.55% to -$304.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$1.1 billion, marking a year-over-year decrease of 1371.77%. This contributed to the annual value of -$1.1 billion for FY2025, which is 1371.77% down from last year.
  • Per Novartis Ag's latest filing, its Interest Expenses stood at -$304.0 million for Q4 2025, which was down 1054.55% from -$281.0 million recorded in Q3 2025.
  • In the past 5 years, Novartis Ag's Interest Expenses registered a high of -$200.0 million during Q1 2023, and its lowest value of -$304.0 million during Q4 2025.
  • Its 5-year average for Interest Expenses is -$231.6 million, with a median of -$216.5 million in 2023.
  • As far as peak fluctuations go, Novartis Ag's Interest Expenses skyrocketed by 1548.12% in 2021, and later crashed by 2672.81% in 2024.
  • Over the past 5 years, Novartis Ag's Interest Expenses (Quarter) stood at -$206.0 million in 2021, then dropped by 0.49% to -$207.0 million in 2022, then fell by 4.83% to -$217.0 million in 2023, then dropped by 26.73% to -$275.0 million in 2024, then dropped by 10.55% to -$304.0 million in 2025.
  • Its Interest Expenses stands at -$304.0 million for Q4 2025, versus -$281.0 million for Q3 2025 and -$289.0 million for Q2 2025.